Programs

Dr. Steidl and Scott teams have successfully won a large-scale applied research project grant worth $11.9 million funded by Genome Canada, Genome BC, Canadian Institutes of Health Research and BC Cancer Foundation to study the genome biology of relapsed lymphoid cancers.

Diffuse large B cell lymphoma (DLBCL) is an aggressive form of B-cell non -Hodgkin lymphoma (NHL) and the most common type of NHL.

Primary mediastinal large B-cell lymphoma (PMBCL) is a rare disease, accounting for 2~-3% of all non-Hodgkin lymphomas (NHL). Based on its clinical and pathological features, it is recognized as a distinct entity by the current World Health Organization Classification.

This team grant is a collaborative effort, whichere experts in lymphoid cancer biomarkers and tumor microenvironment, hematology and cancer genomics jointly aim to understand and overcome treatment failure in lymphoid cancers.